News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genzyme Corporation (GENZ) OKs $2B Buyback, Company to Shed Three Extraneous Units



5/7/2010 8:40:46 AM

New York Times -- The Genzyme Corporation, facing a proxy challenge from the billionaire investor Carl C. Icahn, said it would buy back $2 billion in stock and sell or spin off three units that were not part of its main business in rare-disease drugs, Bloomberg News reported.

Read at Forbes
Read at Wall Street Journal
Read at New York Times
Read at Boston Globe


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES